Latest news : Gamida Cell Ltd.

27/25/27	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/24/22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/24/18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/24/18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/24/18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/24/18	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/24/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/24/10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/24/05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/24/28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/24/28	Top Premarket Decliners	MT
27/24/27	Top Midday Decliners	MT
27/24/27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations : Gamida Cell Ltd.

30/24/30	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/23/15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/23/19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/23/16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases : Gamida Cell Ltd.

27/24/27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/24/27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/24/22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/24/23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/24/29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors : Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	59	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 10:24:51 24/05/2024 pm IST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	26.18L 22.56L 21.36L 19.36L 36.32L 25Cr 36.51L 2.54Cr 97.55L 13Cr 98.33L 96.17L 40Cr	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	3.9Cr 3.36Cr 3.18Cr 2.88Cr 5.41Cr 372.66Cr 5.44Cr 38Cr 15Cr 189.59Cr 15Cr 14Cr 599.09Cr	EV / Sales 2022	-	EV / Sales 2023	5,10,81,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.16
5 years	0.01	4.72
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	4,80,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	2,00,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	2,00,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.52%	26.19L
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+43.40%	+95.27%	6.69TCr
ARGENX SE	-0.23%	-4.45%	+32.50%	+75.75%	6.2TCr
INSMED INCORPORATED	+1.67%	+2.47%	-11.32%	+380.54%	2.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+28.84%	+10.59%	2.46TCr
BIONTECH SE	+0.34%	-6.78%	-0.01%	-16.35%	2.43TCr
GENMAB A/S	+0.43%	-3.37%	+16.22%	-17.99%	1.94TCr
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+181.72%	+335.27%	1.68TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-8.15%	+483.69%	1.42TCr
SUMMIT THERAPEUTICS INC.	+3.24%	-0.31%	-7.34%	+880.45%	1.4TCr
Average	-0.03%	-2.29%	+27.58%	+212.87%	2.7TCr
Weighted average by Cap.	-0.56%	-2.83%	+31.25%	+170.65%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation : Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations : Gamida Cell Ltd.

Press Releases : Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

	2022	2023
Net sales	-	1.78 1.54 1.46 1.32 2.47 170.44 2.49 17.29 6.65 86.71 6.7 6.55 273.99
Net income	-7.94Cr -6.84Cr -6.48Cr -5.87Cr -11Cr -758.31Cr -11Cr -77Cr -30Cr -385.8Cr -30Cr -29Cr -1.22TCr	-6.3Cr -5.43Cr -5.14Cr -4.66Cr -8.74Cr -601.83Cr -8.78Cr -61Cr -23Cr -306.19Cr -24Cr -23Cr -967.52Cr
Net Debt	3.93Cr 3.39Cr 3.21Cr 2.91Cr 5.45Cr 375.53Cr 5.48Cr 38Cr 15Cr 191.05Cr 15Cr 14Cr 603.71Cr	3.64Cr 3.14Cr 2.97Cr 2.69Cr 5.05Cr 347.64Cr 5.07Cr 35Cr 14Cr 176.87Cr 14Cr 13Cr 558.88Cr